Baseline demographic and clinical characteristics of 189 patients receiving brexucabtagene autoleucel infusion by prior InO treatment
| Characteristic . | Inotuzumab naïve, N (%) . | Inotuzumab-exposed, N (%) . | P-value . |
|---|---|---|---|
| Number of patients | 87 | 102 | |
| Median age, (range) years | 48 (18-79) | 45 (21-81) | 0.79 |
| 18-39 | 33 (38) | 44 (43) | 0.80 |
| 40-59 | 28 (32) | 30 (29) | |
| 60+ | 25 (29) | 28 (27) | |
| Sex, female | 37 (43) | 45 (44) | 0.83 |
| Race/ethnicity | 0.85 | ||
| Non-Hispanic White | 49 (56) | 55 (54) | |
| Hispanic | 26 (30) | 30 (29) | |
| Black | 6 (7) | 7 (7) | |
| Asian | 4 (5) | 8 (8) | |
| Other | 2 (2) | 1 (1) | |
| Disease Subtype | 0.003 | ||
| Ph+ | 36 (41) | 19 (19) | |
| Ph-like | 14 (16) | 20 (20) | |
| Ph-negative | 37 (43) | 63 (61) | |
| Pre-apheresis disease status | 0.03 | ||
| Active disease, >5% blasts | 35 (40) | 59 (58) | |
| CR, MRD+ or unknown | 32 (37) | 19 (19) | |
| CR, MRD-neg | 14 (16) | 14 (14) | |
| Missing | 6 (7) | 10 (10) | |
| Pre-apheresis bone marrow blast % | 0.002 | ||
| <25% | 59 (68) | 41 (40) | |
| 25-74% | 8 (9) | 25 (25) | |
| 75% | 5 (6) | 9 (9) | |
| Missing / not performed | 15 (17) | 27 (26) | |
| Extramedullary disease at apheresis | 0.33 | ||
| Yes | 17 (20) | 26 (25) | |
| No | 70 (80) | 76 (75) | |
| CNS involvement at apheresis | 0.37 | ||
| Yes | 18 (21) | 16 (16) | |
| No | 69 (79) | 86 (84) | |
| Number of prior lines of therapy, median (range) | 3 (2-9) | 4 (2-12) | 0.02 |
| Prior blinatumomab therapy | 53 (61) | 59 (58) | 0.67 |
| Prior HCT | 39 (45) | 39 (38) | 0.36 |
| Characteristic . | Inotuzumab naïve, N (%) . | Inotuzumab-exposed, N (%) . | P-value . |
|---|---|---|---|
| Number of patients | 87 | 102 | |
| Median age, (range) years | 48 (18-79) | 45 (21-81) | 0.79 |
| 18-39 | 33 (38) | 44 (43) | 0.80 |
| 40-59 | 28 (32) | 30 (29) | |
| 60+ | 25 (29) | 28 (27) | |
| Sex, female | 37 (43) | 45 (44) | 0.83 |
| Race/ethnicity | 0.85 | ||
| Non-Hispanic White | 49 (56) | 55 (54) | |
| Hispanic | 26 (30) | 30 (29) | |
| Black | 6 (7) | 7 (7) | |
| Asian | 4 (5) | 8 (8) | |
| Other | 2 (2) | 1 (1) | |
| Disease Subtype | 0.003 | ||
| Ph+ | 36 (41) | 19 (19) | |
| Ph-like | 14 (16) | 20 (20) | |
| Ph-negative | 37 (43) | 63 (61) | |
| Pre-apheresis disease status | 0.03 | ||
| Active disease, >5% blasts | 35 (40) | 59 (58) | |
| CR, MRD+ or unknown | 32 (37) | 19 (19) | |
| CR, MRD-neg | 14 (16) | 14 (14) | |
| Missing | 6 (7) | 10 (10) | |
| Pre-apheresis bone marrow blast % | 0.002 | ||
| <25% | 59 (68) | 41 (40) | |
| 25-74% | 8 (9) | 25 (25) | |
| 75% | 5 (6) | 9 (9) | |
| Missing / not performed | 15 (17) | 27 (26) | |
| Extramedullary disease at apheresis | 0.33 | ||
| Yes | 17 (20) | 26 (25) | |
| No | 70 (80) | 76 (75) | |
| CNS involvement at apheresis | 0.37 | ||
| Yes | 18 (21) | 16 (16) | |
| No | 69 (79) | 86 (84) | |
| Number of prior lines of therapy, median (range) | 3 (2-9) | 4 (2-12) | 0.02 |
| Prior blinatumomab therapy | 53 (61) | 59 (58) | 0.67 |
| Prior HCT | 39 (45) | 39 (38) | 0.36 |
Ph, Philadelphia chromosome; CR, complete response; MRD, measurable residual disease; CNS, central nervous system